The Current Landscape of Microbial Biomarkers in Gastrointestinal Disease.

Sohn G Kim, Matthew Y Zhao, Christine Lam, Jonathan P Jacobs

Abstract readReview

In one paragraph

Review in Gastroenterology clinics of North America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sohn G KimUCLA Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Matthew Y ZhaoDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Christine LamDepartment of Medicine, University of California, Los Angeles, CA, USA.

Jonathan P JacobsUCLA Vatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; Division of Gastroenterology, Hepatology and Parenteral Nutrition, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA. Electronic address: jjacobs@mednet.ucla.edu.

Funding

GASTROENTEROLOGYT32DK007180 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JENSEN, DENNIS MICHAEL · 1986 to 2025

$10.0M

NIDDK NIH HHS T32 DK007180

6 · The paper itself

Abstract

The intestinal microbiome encompasses a complex network of microorganisms that is now recognized to make wide contributions to health and disease but remains incompletely understood. Recent studies provide new insights into distinct roles of the microbiome in specific gastrointestinal diseases and support the possibility of developing new clinical microbial biomarkers for disease diagnosis, risk stratification for disease progression, and prediction of response to therapeutic interventions. Here, we discuss the various potential taxonomic, metabolic, and serologic biomarkers that have been highlighted in recent studies.

Indexed as

Gastrointestinal DiseasesGastrointestinal MicrobiomeBiomarkersHumansBiomarkersBiomarkersCancer screeningDiagnosisMicrobiomeResponse predictionRisk stratification

Identifiers

PMID41581948

DOI10.1016/j.gtc.2025.10.003

PMCPMC13023412

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.